In the Phase II MAIA lung cancer trial, THIO improved patients’ overall survival when taken in combination with Libtayo.

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

Detailed results will be presented at an upcoming medical meeting and will be shared with regulatory ... research across diverse stages of skin cancer.” The potential use of Libtayo described above is ...

These findings are expected to be presented at a medical conference and submitted to the U.S. Food and Drug Administration (FDA) in the first half of 2025. Libtayo ... use, and its safety and ...

These findings are expected to be presented at a medical ... Libtayo is already established as a standard of care for certain patients with advanced CSCC. However, its potential new application as an ...

The unapproved uses of EYLEA, EYLEA HD ... These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA ...

Before you receive LIBTAYO, tell your healthcare provider about all your medical conditions, including if you: Your healthcare provider will give you a pregnancy test before you start treatment You ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...